Therapies for multiple sclerosis: translational achievements and outstanding needs

被引：76

作者：

Haghikia, Aiden ^{[1
,2
,3
]}

Hohlfeld, Reinhard ^{[4
,5
]}

Gold, Ralf ^{[3
]}

Fugger, Lars ^{[1
,2
,6
]}

机构：

[1] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England

[2] Univ Oxford, John Radcliffe Hosp, MRC Human Immunol Unit, Weatherall Inst Mol Med, Oxford OX3 9DU, England

[3] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany

[4] Univ Munich, Inst Clin Neuroimmunol, Munich, Germany

[5] Munich Cluster Syst Neurol SyNergy, Munich, Germany

[6] Aarhus Univ Hosp, Inst Clin, DK-8000 Aarhus, Denmark

来源：

TRENDS IN MOLECULAR MEDICINE | 2013年 / 19卷 / 05期

关键词：

multiple sclerosis; IFN beta; glatiramer acetate; TNF receptor 1; dimethyl fumarate monoclonal antibodies; PLACEBO-CONTROLLED TRIAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; MESENCHYMAL STEM-CELLS; DOUBLE-BLIND; GLATIRAMER ACETATE; INTERFERON BETA-1A; CONTROLLED PHASE-3; INTRAMUSCULAR INTERFERON; DISEASE-ACTIVITY; NATALIZUMAB TREATMENT;

D O I：

10.1016/j.molmed.2013.03.004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In recent years, multiple sclerosis (MS) research has progressed on several fronts, prompting numerous clinical trials, primarily for immunotherapeutics. Although several new therapies have been disappointing and some were revealed to have devastating side effects, others have shown benefits and all have generated valuable knowledge about the progression of MS, the key contributors to pathogenesis, and on natural surveillance mechanisms for brain infections. This makes now a useful time to take stock of recent advances in developing MS treatments and consider new approaches for adding information where the gaps are greatest - mainly in understanding the degenerative processes responsible for most of the long-term disability. Here, we summarize currently accepted therapeutic principles and the drugs in late stages of development, as well as spotlighting potential novel openings for future research.

引用

页码：309 / 319

页数：11

共 81 条

[1] Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride [J].

Arun, Tarunya ;

Tomassini, Valentina ;

Sbardella, Emilia ;

de Ruiter, Michiel B. ;

Matthews, Lucy ;

Leite, Maria Isabel ;

Gelineau-Morel, Rose ;

Cavey, Ana ;

Vergo, Sandra ;

Craner, Matt ;

Fugger, Lars ;

Rovira, Alex ;

Jenkinson, Mark ;

Palace, Jacqueline .

BRAIN, 2013, 136 :106-115

[2] Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis [J].

Attfield, Kathrine E. ;

Dendrou, Calliope A. ;

Fugger, Lars .

IMMUNOLOGICAL REVIEWS, 2012, 248 :10-22

[3] MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials [J].

Barkhof, Frederik ;

Simon, Jack H. ;

Fazekas, Franz ;

Rovaris, Marco ;

Kappos, Ludwig ;

de Stefano, Nicola ;

Polman, Chris H. ;

Petkau, John ;

Radue, Ernst W. ;

Sormani, Maria P. ;

Li, David K. ;

O'Connor, Paul ;

Montalban, Xavier ;

Miller, David H. ;

Filippi, Massimo .

NATURE REVIEWS NEUROLOGY, 2012, 8 (01) :13-21

[4] B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells [J].

Barr, Tom A. ;

Shen, Ping ;

Brown, Sheila ;

Lampropoulou, Vicky ;

Roch, Toralf ;

Lawrie, Sarah ;

Fan, Boli ;

O'Connor, Richard A. ;

Anderton, Stephen M. ;

Bar-Or, Amit ;

Fillatreau, Simon ;

Gray, David .

JOURNAL OF EXPERIMENTAL MEDICINE, 2012, 209 (05) :1001-1010

[5] Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy [J].

Bloomgren, Gary ;

Richman, Sandra ;

Hotermans, Christophe ;

Subramanyam, Meena ;

Goelz, Susan ;

Natarajan, Amy ;

Lee, Sophia ;

Plavina, Tatiana ;

Scanlon, James V. ;

Sandrock, Alfred ;

Bozic, Carmen .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20) :1870-1880

[6] Monoclonal anti body-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project [J].

Carson, Kenneth R. ;

Focosi, Daniele ;

Major, Eugene O. ;

Petrini, Mario ;

Richey, Elizabeth A. ;

West, Dennis P. ;

Bennett, Charles L. .

LANCET ONCOLOGY, 2009, 10 (08) :816-824

[7] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial [J].

Cohen, Jeffrey A. ;

Coles, Alasdair J. ;

Arnold, Douglas L. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Fisher, Elizabeth ;

Brinar, Vesna V. ;

Giovannoni, Gavin ;

Stojanovic, Miroslav ;

Ertik, Bella I. ;

Lake, Stephen L. ;

Margolin, David H. ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1819-1828

[8] Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis [J].

Cohen, Jeffrey A. ;

Barkhof, Frederik ;

Comi, Giancarlo ;

Hartung, Hans-Peter ;

Khatri, Bhupendra O. ;

Montalban, Xavier ;

Pelletier, Jean ;

Capra, Ruggero ;

Gallo, Paolo ;

Izquierdo, Guillermo ;

Tiel-Wilck, Klaus ;

de Vera, Ana ;

Jin, James ;

Stites, Tracy ;

Wu, Stacy ;

Aradhye, Shreeram ;

Kappos, Ludwig .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05) :402-415

[9]

Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670

[10] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial [J].

Coles, Alasdair J. ;

Twyman, Cary L. ;

Arnold, Douglas L. ;

Cohen, Jeffrey A. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Miller, Tamara ;

Fisher, Elizabeth ;

Sandbrink, Rupert ;

Lake, Stephen L. ;

Margolin, David H. ;

Oyuela, Pedro ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1829-1839

← 1 2 3 4 5 6 7 8 9 →